Aktuella utlysningar, vecka 6, 2023

Europeiska anslag

Research fellowship. European Academy of Dermatology and Venereology, INT

This fellowship allows young dermatologists, trainees, or junior scientists from other basic science disciplines (post-doctoral scientists) to receive advanced training on basic or clinical research in Dermatology and Venereology in a high standard clinical or research center in a country other than their own for the duration of one year.

The ultimate goal of the fellowship is to support the initiation of an academic career by the Fellow/ Young Investigator, to transfer knowledge and technical skills to the Home Institution and promote the establishment of research collaborations among European and international centers.

ELIGIBILITY CRITERIA

An established agreement between the candidate Fellow and a research or clinical center (Host Institution) that offers excellent research opportunities for the particular research subject and has accepted the candidate for a one year fellowship. The criteria for candidate Fellows are:

The fellow is either way:

• A dermatologist – venereologist,
• A resident in Dermatology – Venereology, or
• A junior scientist with special interest in Dermatology-Venereology (post-doctoral scientist)
• The Fellow can be either of European Nationality (5 positions available) or Non-European Nationality (1 position available).
• The fellow should be under the age of 40 on the day of application.
• The fellow has previous published experience in the field of research he or she is planning to engage in or have a track record in skin research documented by his/her publication records.
• A detailed project that will be submitted by the candidate.

Budget: The EADV Research Fellowship lasts for 12 months and should start within the first trimester of the year after submission (January to March). The EADV Research Fellowship recipient will be supported by a sum of 30’000 euros for their travel and living expenses and their insurance coverage during the training period.

Deadline: 1 April 2023.

More information

Research grants. Cure Parkinson's Trust, GB

The Cure Parkinson's Trust invites applications for its research grants. These support laboratory or clinical research projects that have the potential to cure Parkinson's disease. Applications must be for research that slows, stops or reverses underlying disease progression. Priority is given to research which has potential to translate into the clinic within five years.

Budget: Grants are worth up to £250,000 each.

Deadline: Monday 3 April 2023

More information

Clinical and basic science headache research fellowship award. International Headache Society, INT

The International Headache Association invites applications for its clinical and basic science headache research fellowship award. This supports innovative and impactful research from young investigators in the field of headache. Applications for basic or clinical science headache research, or a combination of basic and clinical research, will be considered.

Eligibility criteria

Applicants must be within six years of completing their last period of training, which may be an MD, PhD or specialty training, not including non-professional periods. Applicants and their mentors must be members of the society.

Budget: The award is worth £50,000 over one year.

Deadline: 8 May 2023

More information
 

Research grants. Centronuclear Myopathies Together Strong, DE

This supports research on treatments and cures for centronuclear myopathies. All researchers worldwide willing to work in the field of centronuclear myopathies are welcome to submit their research proposals in the following priorities:

1. Novel therapeutic approaches to centronuclear myopathies

These approaches may include cellular and molecular approaches that aim to enhance cell function (muscle and other CNM-relevant tissues) such as gene editing, gene replacement therapies, modulation of downstream effects. Furthermore, symptomatic treatments approached directly aiming to improve the quality of life of patients are considered.

2. Cell and Molecular Mechanisms of centronuclear myopathies

Utilization of basic research to improve the understanding of the nature and causes of centronuclear myopathies, so that methods for treatment can be developed.

3. Regenerative Medicine

Development of strategies that provide functional rescue or replacement of degenerated or dysfunctional muscle or other CNM-relevant cells that can lead to improvement of muscle function and/or general physiology.

Budget: Up to 150,000 € for a period of two to three years.

Deadline: April 28th, 2023, 17:00 CET

More information
 

Amerikanska anslag

Federal Funding agencies

2023 Peer Reviewed Medical Research Program (Congressionally Directed Medical Research Programs): DoD

 The FY23 appropriation for PRMRP is $370 million (M). The program seeks applications in laboratory, clinical, behavioral, epidemiological, and other areas of research to advance knowledge in disease etiology; improve prevention, detection, diagnosis, treatment, and quality of life for those affected by a relevant disease or condition; and develop and validate clinical practice or public health guidelines.

The Topic Areas are described below:

• Autoimmune Disorders and Immunology: Celiac Disease • Eczema • Food Allergies • Guillain-Barre Syndrome • Inflammatory Bowel Disease • Neuroinflammatory Responses to Emerging Viral Diseases • Proteomics • Rheumatoid Arthritis • Scleroderma
• Cardiovascular Health: Familial Hypercholesterolemia • Hypercholesterolemia • Proteomics • Vascular Malformations
• Hemorrhage Control and Blood Products: Hemorrhage Control • Proteomics • Trauma
• Infectious Diseases: Hepatitis B • Malaria • Neuroinflammatory Responses to Emerging Viral Diseases • Proteomics • Tuberculosis
• Internal Medicine: Endometriosis • Focal Segmental Glomerulosclerosis • Interstitial Cystitis • Lymphatic Disease • Lymphedema • Nephrotic Syndrome • Pancreatitis • Polycystic Kidney Disease • Pressure Ulcers • Proteomics
• Neuroscience: Eating Disorders • Maternal Mental Health • Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome • Neuroactive Steroids • Neuroinflammatory Responses to Emerging Viral Diseases • Non-Opioid Therapy for Pain Management • Peripheral Neuropathy • Proteomics • Sleep Disorders and Restriction • Suicide Prevention • Trauma
• Orthopaedic Medicine: Arthritis • Orthopaedics • Proteomics • Trauma
• Rare Diseases and Conditions: Dystonia • Ehlers-Danlos Syndrome • Epidermolysis Bullosa • Fibrous Dysplasia/McCune-Albright Syndrome • Fragile X • Frontotemporal Degeneration • Hereditary Ataxia • Hydrocephalus • Mitochondrial Disease • Myotonic Dystrophy • Proteomics • Sickle-Cell Disease • Von Hippel-Lindau Syndrome Benign Manifestations
• Respiratory Health: Proteomics • Pulmonary Fibrosis • Respiratory Health • Trauma
   
• Technology/Therapeutic Development Award
  • Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, and/or quality of life.
  • Supports product-oriented projects (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
  • Funding level 1 is for 2 M USD up to four years; Funding level 2 is for 4 M USD up to four years.
     
• Clinical Trial Award
  • Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.
  • Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
  • A funding limit is not defined; requested funding must be appropriate for the scope of work proposed and up to four years.
     
• Focused Program Award
  • Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal/question.
  • The maximum allowable funding for the entire period of performance is $7.2 million for direct costs and up to four years.
     
• Discovery Award
  • Supports the exploration of a highly innovative new concept or untested theory
  • The maximum allowable funding for the entire period of performance is $200,000 for direct costs and up to two years.
     
• Investigator-Initiated Research Award
• Supports research that will make an original and important contribution to the field of research or patient care in the Topic Area(s) of interest.
• The maximum allowable funding for the entire period of performance is $1.6 million for direct costs for single investigators and $2.0 million for partnering investigators and up to four years.
   
• Lifestyle and Behavioral Health Interventions Research Award
  • Supports the development, evaluation, and implementation of therapies, technologies, and innovations that will enhance patient experience and improve outcomes.
  • The maximum allowable funding for the entire period of performance is $3.0 million for direct costs and up to four years.

Deadline:

• Clinical Trial Award: April 12, 2023 (Pre-application); July 19, 2023 (Full application).
• Focused Program Award: April 12, 2023 (Pre-application); July 19, 2023 (Full application).
• Discovery Award: March 29, 2023 (Pre-application); April 26, 2023 (Full application)
• Investigator-Initiated Research Award: April 19, 2023 (Pre-application); May 31, 2023 (Full application).
• Lifestyle and Behavioral Health Interventions Research Award: April 19, 2023 (Pre-application); May 31, 2023 (Full application)
• Technology/Therapeutic Development Award: April 19, 2023 (Pre-application); May 31, 2023 (Full application).

Funding Opportunity Announcement (FOA):

• Clinical Trial Award: HT9425-23-PRMRP-CTA
• Focused Program Award: HT9425-23-PRMRP-FPA
• Discovery Award: HT9425-23-PRMRP-DA
• Investigator-Initiated Research Award: HT9425-23-PRMRP-IIRA
• Lifestyle and Behavioral Health Interventions Research Award: HT9425-23-PRMRP-LBIRA
• Technology/Therapeutic Development Award: HT9425-23-PRMRP-TTDA

More information 

2023 Breast Cancer Research Program (Congressionally Directed Medical Research Programs): DoD

The FY23 appropriation is $150 million (M). The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Applications must address the challenge in a way that can lead to or make a breakthrough and have a major impact.

• Prevent breast cancer (primary prevention)
• Identify determinants of breast cancer initiation, risk, or susceptibility
• Distinguish deadly from non-deadly breast cancers
• Conquer the problems of overdiagnosis and overtreatment
• Identify what drives breast cancer growth; determine how to stop it
• Identify why some breast cancers become metastatic
• Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
• Revolutionize treatment regimens by replacing them with ones that are more effective, less
  toxic, and impact survival
• Eliminate the mortality associated with metastatic breast cancer
• Breakthrough Award Levels 1 and 2
  • Supports promising research that has high potential to lead to or make breakthroughs in breast cancer.
  • Research should have the potential for a major impact and accelerate progress toward ending breast cancer.
  • The maximum allowable funding for the entire period of performance is between $450,000 to $2M for direct costs and up to four years.
     
• Breakthrough Award Level 3
  • Supports promising research that has high potential to lead to or make breakthroughs in breast cancer.
  • The maximum allowable funding for the entire period of performance is $4M to $5M for direct costs and up to four years.
     
• Breakthrough Award Level 4
  • Supports promising research that has high potential to lead to or make reakthroughs in breast cancer.
  • The maximum allowable funding for the entire period of performance is $15M for direct costs and up to four years.
     
• Innovator Award
  • Supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer.
  • The maximum allowable funding for the entire period of performance is $7M for direct costs and up to four years.
     
• Era of Hope Scholar Award
  • Supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer.
  • The maximum allowable funding for the entire period of performance is $3M for direct costs and up to four years.
     
• Clinical Research Extension Award
  • Supports research that extends the data collection, follow-up, and analysis of breast cancer clinical research studies.
  • The intent of this mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of patient follow-up and sample collection and analysis.
  • The maximum allowable funding for the entire period of performance is $5M to $6M for direct costs and up to four years.

Transformative Breast Cancer Consortium Development Award (New for FY23)

• Provides the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research that will support application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds).
• The maximum allowable funding for the entire period of performance is $100,000 for direct costs and up to one year.

• Transformative Breast Cancer Consortium Award

• Supports collaborations and ideas that will transform or improve the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer.
• The maximum allowable funding for the entire period of performance is $25M for direct costs and up to four years.

Deadlines:

• Breakthrough Award Levels 1 and 2: March 28, 2023 (Pre-Application); April 11, 2023 (Full application).
• Breakthrough Award Level 3: March 29, 2023 (Pre-Application); June 28, 2023 (Full application).
• Breakthrough Award Level 4: March 29, 2023 (Pre-Application); June 28, 2023 (Full application).
• Innovator Award: March 29, 2023 (Pre-Application); June 28, 2023 (Full application).
• Era of Hope Scholar Award: March 28, 2023 (Pre-Application); April 11, 2023 (Full application).
• Clinical Research Extension Award: March 28, 2023 (Pre-Application); April 11, 2023 (Full application).
• Transformative Breast Cancer Consortium Development Award: March 28, 2023 (Pre-Application); April 11, 2023 (Full application).
• Transformative Breast Cancer Consortium Award: March 29, 2023 (Pre-Application); June 28, 2023 (Full application).

Funding Opportunity Announcement (FOA):

• Breakthrough Award Levels 1 and 2: HT9425-23-BCRP-BTA12
• Breakthrough Award Level 3: HT9425-23-BCRP-BTA3
• Breakthrough Award Level 4: HT9425-23-BCRP-BTA4
• Innovator Award: HT9425-23-BCRP-INNOV
• Era of Hope Scholar Award: HT9425-23-BCRP-EOHS
• Clinical Research Extension Award: HT9425-23-BCRP-CREA2
• Transformative Breast Cancer Consortium Development Award: HT9425-23-BCRP-TBCCDA
• Transformative Breast Cancer Consortium Award: HT9425-23-BCRP-TBCCA

More information 

2023 Epilepsy Research Program (Congressionally Directed Medical Research Programs): DoD

The FY23 appropriation is $12.0M. The Epilepsy Research Program (ERP) encourages collaboration among post-traumatic epilepsy (PTE) researchers and urges the scientific community to utilize equitable partnerships with people living with PTE to maximize the translational and impact potential of proposed research.

• Idea Development Award
  • To solicit novel, innovative research that has the potential to increase our understanding of post-traumatic epilepsy (PTE) to improve quality of life, especially in Service Members, Veterans, and/or their care partners. The work should innovatively challenge existing research paradigms or exhibit high levels of creativity.
  • The maximum allowable funding for the entire period of performance is $450,000 to $650,000 for direct costs and up to three years.
• Research Partnership Award
  • To create an avenue to support new or existing collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts. It is expected that investigators utilize their distinct but complementary perspectives to synergistically address a central problem or question critical to PTE research and those living with PTE, their families, and/or their care partners.
  • The maximum allowable funding for the entire period of performance is $1,200,000 for direct costs and up to three years.
• Virtual Post-Traumatic Epilepsy Research Center (P-TERC) Faculty Award

• The P-TERC is a unique, interactive virtual research center providing intensive mentoring, national networking, collaborations, and a peer group for new PTE investigators. The overarching goal of the Virtual P-TERC is to develop successful, highly productive PTE researchers in a collaborative research and career development environment to enhance quality and expand quantity of the PTE research field.
• The maximum allowable funding for the entire period of performance is $525,000 for direct costs and up to three years.

Leveraging Research Award

• To support research that leverages ongoing or completed research studies for which PTE was not an original focus and to provide support to expand the research to develop such a focus and increase our understanding of PTE. The project may include basic, translational, and/or clinical research studies.
• The maximum allowable funding for the entire period of performance is $250,000 for direct costs and up to three years.

Deadlines:

• Idea Development Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full application).
• Research Partnership Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full application).
• Virtual Post-Traumatic Epilepsy Research Center (P-TERC) Faculty Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full application).
• Leveraging Research Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full application).

Funding Opportunity Announcement (FOA):

• Idea Development Award: HT9425-23-ERP-IDA
• Research Partnership Award: HT9425-23-ERP-RPA
• Virtual Post-Traumatic Epilepsy Research Center (P-TERC) Faculty Award: HT9425-23-ERP-Virtual P-TERC-F
• Leveraging Research Award: HT9425-23-ERP-LRA

More information

Team Science Approaches Integrating Experimental and Computational Brain Aging Models (R21/R33 Clinical Trial Not Allowed): NIH

This Funding Opportunity Announcement (FOA) invites applications proposing to establish new, or significantly expand existing, interdisciplinary collaborations involving both experimental and computational researchers to simultaneously address a targeted research question in brain aging and Alzheimer's disease (AD), including AD-related dementias (ADRD).

This FOA utilizes the R21/R33 Phased Innovation Award activity code. The R21 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities.

The aim of this initiative is for investigators to develop a sustainable, interdisciplinary collaboration across experimental and computational laboratories to support projects that address key research questions in brain aging and AD/ADRD.

Deadline: September 22, 2023. Applications are due by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-AG-24-018

RFA-AG-24-018: Team Science Approaches Integrating Experimental and Computational Brain Aging Models (R21/R33 Clinical Trial Not Allowed) (nih.gov)

Foundations
 

Rolling Review of Pre-proposals for Pre-clinical and Clinical Therapeutic Development, Michael J. Fox Foundation (MJFF), US
The Michael J. Fox Foundation extends the Therapeutics Pipeline Program to accept pre-proposals aimed at clinical therapeutic development, in addition to proposals from the pre-clinical track previously announced. The program seeks applications on a rolling basis aimed at developing and testing therapeutic interventions. For this program, MJFF will prioritize applications from industry groups and academia-industry partnerships.

Eligibility: industry + academia partnerships

Deadlines: March 23; May 25; July 27, 2023. Applicants will be notified of a decision within 3 months of the full proposal submission period.

Parkinson's Disease Therapeutics Pipeline Program | Parkinson's Disease (michaeljfox.org)

AACR Breast Cancer Research Fellowships, American Association for Cancer Research (AACR) US

The AACR Breast Cancer Research Fellowships represent a joint effort to encourage and support postdoctoral or clinical research fellows to conduct breast cancer research and to establish a successful career path in this field. The research proposed for funding may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to breast cancer.

These fellowships provide two-year grants of $120,000 to support the salary and benefits of the fellow while working on mentored breast cancer research.

Deadlines: March 23, 2023 1:00 PM

AACR Breast Cancer Research Fellowships | AACR Grants